DEFA14A: LAVA, XOMA Amend Deal: Lower Cash, New CVR Terms

LAVA Therapeutics and XOMA Royalty amend their share purchase agreement, reducing the cash per share to $1.04 and adjusting contingent value rights, while extending the tender offer and reconvening the EGM.

Summary

• LAVA Therapeutics N.V. and XOMA Royalty Corporation have amended their Share Purchase Agreement, dated August 3, 2025.
• The cash consideration per share for tendered shares has been reduced to $1.04, down from the original range of $1.16 to $1.24.
• The Contingent Value Right (CVR) terms have been updated to include a new right for holders to receive up to approximately $0.23 per CVR, depending on the final determination of certain potential liabilities.
• The minimum Closing Net Cash condition for the consummation of the Offer has been lowered to $24.5 million, from the previous $31.5 million.
• The tender offer expiration has been extended from October 17, 2025, to November 12, 2025.
• LAVA intends to reconvene its Extraordinary General Meeting of Shareholders (EGM) on November 7, 2025, to approve matters related to the transactions.
• The changes reflect the parties' current understanding of potential liabilities, associated expenses, and LAVA's expected cash balance at closing.

Sentiment

Score: 4

Explanation: The reduction in the cash component of the offer consideration is a clear negative for shareholders. However, the lowering of the minimum net cash condition and the inclusion of a new CVR component related to potential liabilities could be seen as improving the likelihood of the deal closing and offering some additional, albeit speculative, value. The non-transferability of CVRs limits their immediate value.

Positives

• The amendment and extension indicate continued progress towards the acquisition, potentially increasing deal certainty.
• The lowered minimum Closing Net Cash condition to $24.5 million makes it more likely that the acquisition conditions will be met.
• A new CVR component offers potential additional payments of up to approximately $0.23 per CVR, tied to the resolution of certain potential liabilities.
• Existing partnerships with Pfizer Inc. and Johnson & Johnson for key drug candidates (EGFRd2 and JNJ-89853413) remain a source of potential future CVR value.

Negatives

• The cash consideration per share has been reduced to $1.04, a decrease from the previously agreed range of $1.16 to $1.24.
• Contingent Value Rights (CVRs) are generally non-transferable, limiting liquidity for shareholders who receive them.
• The value of CVR payments is highly speculative and subject to numerous factors outside of Parent's control, with no assurance of any payments.
• The changes were prompted by a current understanding of potential liabilities and associated expenses, suggesting unforeseen financial challenges.

Risks

• Various closing conditions, including the minimum tender percentage of shares, may not be satisfied or waived.
• Competing offers for LAVA Therapeutics N.V. could emerge.
• The transactions may not be completed in a timely manner, or at all, which could adversely affect LAVA's business and share price.
• Shareholder or other litigation in connection with the transactions may result in significant costs of defense, indemnification, and liability.
• Activities related to the CVR Agreement, including the new form thereof, may not result in any value or payments to LAVA's shareholders.
• LAVA's or XOMA Royalty's business may experience significant disruptions due to transaction-related uncertainty prior to completion.
• The announcement and pendency of the transactions may make it more difficult to establish or maintain relationships with employees, manufacturers, suppliers, vendors, or business partners.
• General economic and market conditions, including inflation, heightened interest rates, health crises, and geopolitical conflicts, could adversely affect LAVA's business condition and results.
• Tax Reserve Matter Expenses could exceed the $6,333,000 reserve, potentially reducing or eliminating Tax Reserve Proceeds for CVR holders.

Future Outlook

The proposed acquisition is expected to close in the fourth quarter of 2025, subject to customary closing conditions, including shareholder approval and the tender of a minimum percentage of shares. XOMA Royalty aims to monetize LAVA's partnered and unpartnered programs for the benefit of CVR holders. LAVA will file a revised definitive proxy statement for the reconvened EGM.

Management Comments

• "LAVA and XOMA Royalty are entering into the Amendment in light of their current understanding of potential liabilities, associated expenses, and the most recent estimates of LAVAs expected cash balance at closing."

Industry Context

This amendment reflects ongoing M&A activity in the biotechnology sector, where larger entities like XOMA Royalty (a royalty aggregator) acquire smaller biopharmaceutical companies like LAVA Therapeutics for their pipeline assets and intellectual property. LAVA's focus on clinical-stage bispecific gamma delta T cell engagers and its partnerships with major pharmaceutical companies (Pfizer, Johnson & Johnson) highlight the strategic value of its therapeutic candidates. The adjustments to deal terms, particularly cash and contingent value rights, are common in biotech acquisitions, often reflecting evolving assessments of asset value, development risks, and financial liabilities.

Corporate Governance

Related Party Transactions

• The amendment to the Share Purchase Agreement is between LAVA Therapeutics N.V. and XOMA Royalty Corporation, detailing the terms of the acquisition.
• The Contingent Value Rights Agreement involves XOMA Royalty Corporation (Parent) and includes LAVA's President and CEO, Stephen Hurly, and XOMA Royalty's CEO, Owen Hughes, as members of the Tax Reserve Committee, acting on behalf of CVR holders.

Stakeholder Impact

• Shareholders: Will receive a reduced cash consideration per share but gain a new, albeit speculative, CVR component related to potential liabilities. Deal certainty may be improved due to adjusted conditions.
• Employees: May experience disruptions due to transaction-related uncertainty, potentially impacting relationships and morale.
• Management: Key executives are involved in the Tax Reserve Committee, aligning their interests with CVR holders for specific tax matters.
• Partners (Pfizer, Johnson & Johnson): Existing collaboration agreements are integral to the CVR value, implying continued engagement and potential for future proceeds.

Next Steps

• XOMA Royalty will file an amendment to its Tender Offer Statement on Schedule TO with the SEC.
• LAVA will file an amendment to its Solicitation/Recommendation Statement on Schedule 14D-9 with the SEC.
• LAVA will file an amended definitive proxy statement in connection with the reconvened EGM.
• LAVA shareholders are urged to read the proxy statement and tender offer materials before making any decision.
• The Extraordinary General Meeting of Shareholders will be held on November 7, 2025, for shareholders to vote on proposed resolutions.
• The tender offer is scheduled to expire on November 12, 2025, unless further extended or terminated.
• The proposed acquisition is expected to close in the fourth quarter of 2025, followed by a corporate reorganization.

Key Dates

Recommendation

While the cash consideration per share has been reduced, which is a negative, the amendment also lowers the minimum net cash condition, potentially increasing the likelihood of the acquisition closing. The inclusion of a new CVR component tied to potential liabilities offers a speculative upside. Given the deal is still pending shareholder approval and tender, and the CVRs are non-transferable, a 'Hold' recommendation is appropriate for existing shareholders to await the finalization of the offer and assess the CVR's potential value, rather than selling at a potentially depressed price or buying into a speculative CVR.

Keywords

Biotechnology, Pharmaceuticals, Mergers and Acquisitions, Tender Offer, Contingent Value Right, LAVA Therapeutics, XOMA Royalty, SEC Filing, Corporate Governance, Risk Management, Drug Development, Clinical Stage